Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

New Model for Classifying Types of Batten Disease Proposed

Researchers have proposed an alternate classification model for Batten disease types based on the site first affected by each type and how it progresses. They tested their hypothesis in two of the most common Batten types. A comprehensive analysis of published data so far showed infantile Batten disease…

EEG or MRI Alone Not Enough to Diagnose CLN2, Panel Agrees

Although electroencephalogram (EEG) and MRI findings may detect early signs of ceroid lipofuscinosis type 2 disease (CLN2), they cannot diagnose the condition independently, according to a panel of disease specialists. For an early diagnosis, the panel recommends that genetic testing be initiated soon after early clinical and EEG/MRI abnormalities…

FDA OKs Trial of NGN-101 Gene Therapy in CLN5 Patients

The U.S. Food and Drug Administration (FDA) has cleared Neurogene’s request to conduct a Phase 1/2 clinical trial to evaluate the safety, tolerability, and efficacy of NGN-101, an investigational gene therapy to treat CLN5, a form of late-infantile Batten disease. The therapy uses a harmless adeno-associated virus (AAV)…

Animal Models Can Predict Brineura Doses for CLN2 Patients

Animal models predicted dosing of the enzyme replacement therapy Brineura (cerliponase alfa) for patients with late infantile Batten disease, also called CLN2 disease, a study showed. Scientists said this approach also may be applied to predict cross-species dosing for other similar medicines. “Overall, the approach described here provides…